ASH 2022 | AUGMENT-101: insights into the use of revumenib to treat patients with AML
Ghayas Issa, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into two studies evaluating the use of the menin inhibitor revumenib for the treatment of patients with acute myeloid leukemia (AML). Dr Issa begins by summarizing the AUGMENT-101 study (NCT04065399), which assessed the optimal dosage of revumenib in patients with KMT2A-rearranged or NPM1-mutant AML, and demonstrated that patients treated with this agent achieved durable responses. Following this, Dr Issa highlights the findings of a follow-up study that investigated the role of revumenib in patients following hematopoietic stem cell transplant (HSCT). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis, Kura Oncology, Nuprobe: Consultancy; Celgene, Kura Oncology, Syndax, Merck, Cullinan and Novartis: Research Funding.
